USUma Sinha

Uma Sinha

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Uma Sinha has a total of 49 co-authors. Here are the top co-authors by number of shared publications:

  • Nilanjan Sengupta

    Department of Endocrinology, Nilratan Sircar Medical College, Kolkata, India

    4 shared publications
  • Keshab Sinharay

    Department of Medicine, Nilratan Sircar Medical College, Kolkata, West Bengal, India

    3 shared publications
  • Gautam Gangopadhyay

    Department of Neurology, Bangur Institute of Neurosciences, Institute of Post-Graduate Medical Education and Research and Seth Sukhlal Karnani Memorial Hospital, Kolkata, West Bengal, India

    2 shared publications
  • Keshab Sinha Roy

    Department of Medicine, NRSMC, Kolkata, West Bengal, India

    2 shared publications
  • Prasanta Mukhopadhyay

    Department of Medicine, Nilratan Sircar Medical College, Kolkata, India

    2 shared publications
  • Sudipta Saha

    Department of Medicine, Nilratan Sircar Medical College, Kolkata, West Bengal, India

    2 shared publications

Latest Publications

  • Open Access

    A Study on Protocol-based Treatment Change in Drug-resistant Epilepsy Patients in a Tertiary Care Center in Eastern India

    by Saumen Bhat, Uma Sinharoy, Jayanta Ghosal, Gautam Gangopadhyay

    Background and Objectives: Management of drug-resistant epilepsy (DRE) remains challenging. A considerable subset of such patients who cannot access nonpharmacological treatment options relies on antiseizure medication (ASM) combination therapy, for which no standardized guidelines currently exist. This study aimed to determine the efficacy of treatment changes using a clinic-based strategic treatment protocol in patients with DRE. Furthermore, it sought to identify clinical factors associated with a positive patient response to these adjustments. Methods: We conducted a prospective observational study including 138 patients with DRE who were followed for 24 months. Seizure frequency was assessed at 3, 6, and 12 months. Results: A total of 469 drug-changing interventions were performed across the cohort (284 for focal epilepsy and 185 for generalized and unknown seizures). Key findings included: (1) Seizure reduction: Univariate analysis revealed a statistically significant reduction in seizure frequency at the 3-, 6-, and 12-month follow-ups (22% and 41% reduction at 6 and 12 months, respectively; P = 0.0146, P = 0.0014, and P = 0.0001, respectively). (2) Predictive factors: Multivariate analysis demonstrated that age at disease onset, disease duration, and number of ASMs prescribed both before the index date and at 6 and 12 months were statistically significant predictors of therapeutic response ( P < 0.05). (3) Remission rates: At the 12-month follow-up after rescheduling, 19.56% (n = 27) of patients achieved complete seizure freedom. Conclusions: Modifying ASM regimens through a strategic protocol yielded significant improvements in seizure control in patients with DRE during the one-year follow-up period. Clinical and treatment-related factors independently predicted outcomes.

  • Open Access

    Association of SCN1A and SCN2A Gene Polymorphisms with Antiseizure Medication Responsiveness: A Case-Control Study from Eastern India

    by Kollipara Sumanth, Uma Sinharoy, Anindita Joardar, Sarnava Roy, Alak Pandit, Gautam Gangopadhyay

    Background and Objectives: Epilepsy, with its complex interplay of neurobiological, genetic, and pharmacological factors, continues to challenge neurologists worldwide—particularly in managing drug resistance. This study aimed to evaluate the frequency of the SCN1A and SCN2A gene polymorphisms among patients with epilepsy (PWE) from Eastern India to assess their relationship with clinical profiles, electroencephalography (EEG) findings, and response to antiseizure medication. Methods: In this case–control genetic association study, a total of 110 PWE were assessed for demographic and clinical profiles, EEG and neuroimaging findings, and treatment response. SCN1A and SCN2A gene polymorphisms (five selected intronic single nucleotide polymorphisms [SNPs]—four in SCN1A [rs2298771, rs6730344, rs10167228, rs6732655] and one in SCN2A [rs17183814]) were assessed through polymerase chain reaction and restriction fragment length polymorphism. Results: In the present study cohort, we observed that the generalized seizure type (73.6%) and early-onset seizures (mean 7.4 years in drug-resistant epilepsy [DRE]) were significantly more frequent in drug-resistant persons. The SCN2A rs17183814 AG genotype frequencies were 36/92 (39.1%) in DRE, 10/18 (55.6%) in responders, and 46/110 (41.8%) in controls. Statistical comparison showed no significant association between the AG genotype and drug resistance (DRE vs. responders: odds ratio [OR] 0.51, 95% confidence interval [CI] 0.19–1.43, P = 0.303; DRE vs. controls: OR 0.89, 95% CI 0.51–1.57, P = 0.808). Conclusions: On genetic analysis, the AG genotype of SCN2A rs17183814 was numerically higher among responders than DRE, but the difference was not significant. None of the SCN1A SNPs studied ( rs2298771, rs6730344, rs10167228, rs6732655 ) showed significant associations with treatment response, consistent with previous Indian reports.

  • Open Access

    Clinical Presentation, Demographic Profile, Outcome, and Treatment Gap of Large Vessel Stroke – A Study from a Tertiary Care Hospital in Eastern India

    by Rajdeep Saha, Uma Sinharoy, Biman Kanti Ray

    Objectives: Large vessel occlusion (LVO) stroke is typically more severe and associated with less favorable outcomes. But LVOs also provide an opportunity for neurovascular intervention in the form of endovascular therapy (EVT) within golden hours. This study is aimed to identify the time gap as well as treatment gap in LVO stroke at the primary care level, along with its risk factors and clinical features. Methodology: This prospective observational study included data from 104 patients with LVO stroke on Day 0, 7, or at the time of discharge and at 3 months over a period of 18 months. Glasgow Coma Scale, National Institute of Health Stroke scale (NIHSS), Modified Rankin Scale (MRS) and Barthel index were used for patient monitoring. SPSS version 27 was used for data analysis. Results: Majority of the cohort belonged to be middle-aged with a male preponderance. Hypertension (69.23%), diabetes (43.27%), addiction (54.82%), and anterior circulation LVO (81.7%) with aphasia (18.27%) were prevalent. About 55.8% of LVO patients attended primary care level after 4.5 h of their symptoms (mean time of 6.86 h). 64.4% of the study population was diagnosed as LVO more than 24 h later. NIHSS score at Day 0, with positive correlation with computed tomography collateral score and outcome (MRS score at day 7 and 90), was a significant observation. Conclusion: NIHSS score (Day 0), MRS during discharge, duration, and complications of hospital stay significantly affected long-term outcome. Significant correlation was found between socioeconomic status and education of the patients with time to identification of LVO.

  • Open Access

    Spectrum of Neurological Adverse Events Following COVID-19 Vaccination: An Observational Study From a Tertiary Care Centre of Eastern India

    by Uddalak Chakraborty, Biman Kanti Ray, Alak Pandit, Soumita Sadhukhan, Arijit Roy, Saumen Bhat, Aishee Bhattacharyya, Rajdeep Saha, Arindam Santra, Sujoy Kabiraj, et al.

    Background: As the world tends to recover from the crisis created by the COVID-19 pandemic, vaccines have served as one of the most valuable tools of combat and large-scale immunization has helped to tide over the catastrophe. However, several reports of post -vaccination neurological complications around the globe have surfaced up in recent literature. This study was conducted with an aim to describe the spectrum of neurological ailments requiring hospitalization following COVID-19 vaccination.Methods: An ambispective observational study was carried out from March 2021 to February 2022 at a tertiary care institute with 25 patients who satisfied the inclusion criteria of a new onset neurological illness requiring hospitalization within 4 days to 42 days of vaccination. The patients were duly followed upto months after discharge.Results: The median age of the sample was 36 years and the median latency of onset of neurological events was 14 days. Guillain-Barré syndrome was documented in 11 patients; majority were acute motor axonal neuropathy (45.45%) followed by acute inflammatory demyelinating polyradiculoneuropathy (36.36%) and acute motor sensory axonal neuropathy (18.18%). Central nervous system demyelination was reported in 9 patients; two patients had acute disseminated encephalomyelitis, 2 patients were diagnosed with myelin oligodendrocyte glycoprotein antibody-associated disease, one patient with aquaporin-4 positive neuromyelitis optica spectrum disorder , and the rest were labelled as seronegative central nervous system demyelination. Vascular events were noted in 5 patients comprising of 2 cases each of cerebral venous sinus thrombosis and intracerebral hemorrhage and a case of Moyamoya angiopathy. All patients were conservatively managed and had a complete to partial recovery suggestive of a favorable outcome after 3 months. Conclusion: The pathomechanisms of post -vaccination neurological complications is yet to be elucidatedand any causal association attributable to vaccination warrants further research. Compared to the enormity of the vaccinated population, the adverse effects are miniscule to hinder and discourage vaccination.

  • Open Access

    Serum 25-Hydroxyvitamin D Level Estimation among Patients with Parkinson's Disease in West Bengal, India, and its Relationship with Motor Impairment

    by Uma Sinharoy, Shankar Prasad Saha

    Context: Worldwide, the association of Vitamin D deficiency in Parkinson's disease (PD) has recently been proposed. However, to the best of our knowledge, such studies are lacking from eastern India. Aims: This study compares the prevalence of Vitamin D deficiency in a cohort of patients with PD with the prevalence in age-matched healthy controls. It also aimed at determining a significant correlation of the severity of the various motor manifestations in PD with low serum vitamin levels. Settings and Design: It was a prospective observational case–control study to estimate the level of serum 25-hydroxyvitamin D (25[OH] D) concentrations of the sample population. Subjects and Methods: One hundred consecutive PD patients were selected for this study between 2015 and 2018 from the patients attending neurology outpatient department. Control (n = 100) participants were randomly selected after matching for age sex, and geographic location. Statistical Analysis Used: Statistical Package for the Social Sciences version 15 with multivariate logistic regression (the Pearson correlation coefficient (r) and P value) was applied. Results: Among 100 PD patients 48, patients (48%) had Vitamin D deficiency, 34 patients (34%) had Vitamin D insufficiency, and 18 patients (18%) had normal Vitamin D level; whereas age- and sex-matched control population shows Vitamin D deficiency in 46% people, normal vitamin level in 42%, and insufficient Vitamin D level in 12% control population. The mean (standard deviation) 25(OH) D concentration in the PD cohort was significantly lower than in the control cohorts (20.72 [8.21] ng/mL vs. 25.56 [11.99] ng/mL, respectively; P = 0.001). There was major association between 25(OH) D levels and severity of motor scores (P = 0.028), tremor (P = 0.0001), bradykinesia (P = 0.001), and severity of freezing (P = 0.002), whereas no significant association was found between Vitamin D levels and rigidity (P = 0.05) and postural instability (P = 0.395). Conclusions: This study demonstrates a significantly higher prevalence of hypovitaminosis in PD versus healthy controls. The severity of motor scores, tremor, and bradykinesia and severity of freezing were found to have a direct inverse correlation with low serum Vitamin D levels which further emphasizes the provision of preventive and therapeutic supplementation of Vitamin D in PD.


  • Open Access

    Thyroid disorders in polycystic ovarian syndrome subjects: A tertiary hospital based cross-sectional study from Eastern India

    by Uma Sinha, Keshab Sinharay, Sudipta Saha, T Amenla Longkumer, Shuvra Neel Baul, Salil Kumar Pal

    Context: Polycystic ovarian syndrome (PCOS), the most common endocrinopathy of women in the reproductive age group seems to be adversely affected by associated thyroid dysfunction. Both pose independent risks of ovarian failure and pregnancy related complications. Aims: The present study from Eastern India is, therefore, aimed to investigate the prevalence and etiology of different thyroid disorders in PCOS subjects. Settings and Design: Cross-sectional hospital based survey-single centre observational case-control study. Materials and Methods: This prospective single-center study recruited 106 female patients with hypertrichosis and menstrual abnormality among which 80 patients were defined as having PCOS according to the revised 2003 Rotterdam criteria and comprised the study population. Another 80 age-matched female subjects were studied as the control population. Thyroid function and morphology were evaluated by measurement of serum thyroid stimulating hormone (TSH), free thyroxine levels (free T3 and free T4), anti-thyroperoxidase antibody (anti-TPO Ab), clinical examination and ultrasound (USG) of thyroid gland. Statistical Analysis Used: It was done by Student's t-test and Chi-square test using appropriate software (SPSS version 19). Results: This case-control study revealed statistically significant higher prevalence of autoimmune thyroiditis, detected in 18 patients (22.5% vs. 1.25% of control) as evidenced by raised anti-TPO antibody levels (means 28.037 ± 9.138 and 25.72 ± 8.27 respectively; P = 0.035). PCOS patients were found to have higher mean TSH level than that of the control group (4.547 ± 2.66 and 2.67 ± 3.11 respectively; P value < 0.05). There was high prevalence of goiter among PCOS patients (27.5% vs. 7.5% of control, P value < 0.001). On thyroid USG a significantly higher percentage of PCOS patients (12.5%; controls 2.5%) had hypoechoic USG pattern also compatible with the diagnosis of autoimmune thyroiditis. Conclusions: High prevalence of thyroid disorders in PCOS patients thus points towards the importance of early correction of hypothyroidism in the management of infertility associated with PCOS.


  • Open Access

    Recurrent hypokalemic paralysis: An atypical presentation of hypothyroidism

    by Uma Sinha, Nilanjan Sengupta, Keshab Sinharay, Pranab K. Sahana

    Hypothyroidism presenting as recurrent hypokalemic paralysis is rare in the literature. This transient and episodic neurological condition is commonly associated with thyrotoxicosis. We report a case of young female admitted with recurrent paralytic attacks since last 1 year. She had no symptom of hypothyroidism. She had weakness of all four limbs, delayed relaxation of ankle jerks, and normal higher mental function. There was no enlargement of thyroid. Serum potassium level ranged from 1.6 to 3.2 meq/L during attack with high serum creatine phosphokinase level. Electromyography was normal. The patient was diagnosed having chronic thyroiditis with high thyroid-stimulating hormone and thyroid-related antibodies. Follow up shows satisfactory result with thyroxine replacement. It is an extremely rare and unusual presentation of hypothyroidism, probably the fourth reported case of hypothyroidism with hypokalemic paralysis, to the best of our knowledge.


  • Open Access

    Benefits of leptin therapy in HIV patients

    by Uma Sinha, Keshab Sinharay, Nilanjan Sengupta, Prasanta Mukhopadhyay

    Leptin therapy in human recombinant form has recently been used in HIV-associated lipodystrophy syndrome on experimental basis in some small short-term clinical trials. It has shown its beneficial effects only in hypoleptinemic HIV-infected patients by causing definite improvement in their insulin sensitivity, glucose tolerance, lipid status, and truncal obesity. Leptin prevents lipotoxicity and activates insulin signaling pathways through several postulated mechanisms. Central leptin insufficiency with peripheral hyperleptinemia has come out to be a significant contributor to the development of obesity and metabolic syndrome. In this article, we will review the basis of leptin therapy in HIV patients, with its promises. However, further larger clinical trials are needed to prove its long-term efficacy in the control of metabolic complications related to HIV therapy.


  • Open Access

    Acromegaly without acral changes: A rare presentation

    by Uma Sinha, Nilanjan Sengupta, Keshab Sinha Roy, Sudipta Saha

    Acromegaly is diagnosed clinically by the universal presence of acral enlargement and typical coarse facies. We report a short, elderly female developing acromegalic facies for last 10 years without acral overgrowth. She is a patient of primary hypothyroidism, well controlled for last 20 years. Acromegaly was proven by high level of serum insulin like growth factor-1 (IGF-1) and elevated and nonsuppressed level of growth hormone (GH), with other hormonal profile being undisturbed. She had mild insulin resistance and systemic hypertension in absence of any visual field defect. Magnetic resonance imaging (MRI) of brain revealed pituitary hyperplasia without any detectable adenoma. No source of ectopic secretion of GH or growth hormone releasing hormone (GHRH) could be localized. Therefore, atypical presentation of acromegaly needs high degree of suspicion even if some of the common features are lacking. Here, we have biochemically proved acromegaly with typical facies, short stature but no acral overgrowth and pituitary adenoma despite longstanding disease activity, and thus eluding diagnosis for years.

  • Open Access

    Human immunodeficiency virus endocrinopathy

    by Uma Sinha, Nilanjan Sengupta, Prasanta Mukhopadhyay, Keshab Sinha Roy

    Human immunodeficiency virus (HIV) endocrinopathy encompasses a broad spectrum of disorders. Almost all the endocrine organs are virtually affected by HIV infection. HIV can directly alter glandular function. More commonly secondary endocrine dysfunction occurs due to opportunistic infections and neoplasms in immunocompromised state. The complex interaction between HIV infection and endocrine system may be manifested as subtle biochemical and hormonal perturbation to overt glandular failure. Antiretroviral therapy as well as other essential medications often result in adverse endocrinal consequences. Apart from adrenal insufficiency, hypogonadism, diabetes and bone loss, AIDS wasting syndrome and HIV lipodystrophy need special reference. Endocrinal evaluation should proceed as in other patients with suspected endocrine dysfunction. Available treatment options have been shown to improve quality of life and long-term mortality in AIDS patients.